Pfizer (NYSE:PFE) stock is expected to deviate a maximum of $5.51 from the average target price of $38.85 for the short term period. 13 Street Experts have initiated coverage on the stock with the most promising target being $54 and the most muted being $33.
Other Equity analysts have also commented on the company shares. Jefferies maintains their rating on the shares of Pfizer (NYSE:PFE). The current rating of the shares is Buy. Equity Analysts at the Firm raises the price target to $42 per share from $41 per share. The rating by the firm was issued on June 14, 2016.
Pfizer (NYSE:PFE): stock turned positive on Thursday. Though the stock opened at $34.7, the bulls momentum made the stock top out at $34.74 level for the day. The stock recorded a low of $34.3 and closed the trading day at $34.59, in the green by 0.35%. The total traded volume for the day was 23,824,757. The stock had closed at $34.47 in the previous days trading.
The company shares have rallied 1.32% from its 1 Year high price. On Jul 31, 2015, the shares registered one year high at $36.46 and the one year low was seen on Feb 8, 2016. The 50-Day Moving Average price is $34.21 and the 200 Day Moving Average price is recorded at $31.87. On the companys insider trading activities, The officer (Executive Vice President), of Pfizer Inc, Damelio Frank A had unloaded 100,000 shares at $34.49 per share in a transaction on May 26, 2016. The total value of transaction was $3,449,000. The Insider information was revealed by the Securities and Exchange Commission in a Form 4 filing.
Pfizer Inc. is a global biopharmaceutical company. The Company is engaged in discovering, developing and manufacturing of healthcare products. Its products include Lyrica, the Prevnar family of products, Enbrel, Celebrex, Lipitor, Viagra, Zyvox, Sutent, EpiPen, Toviaz, Tygacil, Rapamune, Xalkori, Inlyta, Norvasc, BeneFIX, Genotropin and Enbrel, among others. It operates in three segments: Global Innovative Pharmaceutical segment (GIP), Global Vaccines, Oncology and Consumer Healthcare segment (VOC) and Global Established Pharmaceutical segment (GEP). GIP is focused on developing, registering and commercializing medications in therapeutic areas, such as inflammation, cardiovascular/metabolic, neuroscience and pain, rare diseases and womens/mens health. VOC focuses on the development and commercialization of vaccines and products for oncology and consumer healthcare. GEP includes its sterile injectable products and bio similar development portfolio. Its subsidiary is Hospira, Inc.